Details for Patent: 10,420,841

« Back to Dashboard

Which drugs does patent 10,420,841 protect, and when does it expire?

Patent 10,420,841 protects ZERBAXA and is included in one NDA.

Protection for ZERBAXA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in twenty-eight countries.

Summary for Patent: 10,420,841

Title:	Ceftolozane antibiotic compositions
Abstract:	This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
Inventor(s):	Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandron DONADELLI, Dario Resemini
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US15/844,961
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,420,841

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes					Y

International Family Members for US Patent 10,420,841

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014227660
Australia	2015200599
Brazil	112015023523
Canada	2906151